DalsnaFinance

ABBV: $10.9B acquisition adds innovative immunology assets, targeting blockbuster growth by 2032

Stocks TradingView By TradingView 22 Jun 2026 22:49 1 min read
ABBV: $10.9B acquisition adds innovative immunology assets, targeting blockbuster growth by 2032

ABBV: $10.9B acquisition adds innovative immunology assets, targeting blockbuster growth by 2032  TradingView

ABBV: $10.9B acquisition adds innovative immunology assets, targeting blockbuster growth by 2032 TradingView

Read the full story on TradingView → Opens the original article on news.google.com

Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.